Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geodrill Announces Record First Quarter 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biofrontera Equity Warrants 27th Oct 2026 BFRIW

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Recent & Breaking News (NDAQ:BFRIW)

Biofrontera Inc. Announces Closing of $9.4 Million Private Placement

GlobeNewswire May 19, 2022

Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement

GlobeNewswire May 16, 2022

Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire May 13, 2022

Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

GlobeNewswire May 6, 2022

Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

GlobeNewswire May 5, 2022

Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®

GlobeNewswire April 21, 2022

Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®

GlobeNewswire April 13, 2022

Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

GlobeNewswire April 8, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022

GlobeNewswire April 6, 2022

Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022

GlobeNewswire April 1, 2022

Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting

GlobeNewswire March 17, 2022

Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040

GlobeNewswire March 14, 2022

Biofrontera Inc. to Present at the 34th Annual Roth Conference

GlobeNewswire March 9, 2022

Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors

GlobeNewswire March 7, 2022

Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT

GlobeNewswire February 1, 2022

Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond

GlobeNewswire January 18, 2022

Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

GlobeNewswire January 13, 2022

Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January

GlobeNewswire January 10, 2022

Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

GlobeNewswire December 30, 2021

Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe Acne

GlobeNewswire December 13, 2021